Source: International Congress 2018 – New developments in the treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Zamarron De Lucas (Madrid, Spain), D. Romero Ribate (Madrid, Spain), J. Fernández-Lahera Martínez (Madrid, Spain), C. Villasante Fernández-Montes (Madrid, Spain), S. Quirce Gancedo (Madrid, Spain), P. Barranco Sanz (Madrid, Spain), J. Domínguez Ortega (Madrid, Spain), R. Álvarez-Sala Walther (Madrid, Spain). Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients?. 1038

Member's Comments

No comment yet.

Related content which might interest you: Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007 Risk factors for severe exacerbations in a real-life population of adults with severe refractory asthma Source: International Congress 2017 – Many faces of asthma and allergies Year: 2017 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Asthma patients adjust their maintenance treatment late in response to worsening asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 7s Year: 2005 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Factors resulting in uncontrolled severe persistent asthma in children Source: Eur Respir J 2004; 24: Suppl. 48, 20s Year: 2004 Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma Source: Eur Respir J, 58 (6) 2100413; 10.1183/13993003.00413-2021 Year: 2021 Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 The Anglo-French real-life experience of maintenance OCS use in omalizumab-treated patients with severe persistent allergic asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Effect of maintenance oral corticosteroids on risk factors for frequent exacerbations in a severe adult asthma population Source: Virtual Congress 2020 – Severe asthma phenotypes and outcomes Year: 2020 Factors associated with frequent exacerbations in patients with severe asthma Source: Eur Respir J 2001; 18: Suppl. 33, 369s Year: 2001